Roche CEO Schwan on Profit Forecast, Drug Pipeline

The transcript discusses the strong performance of newly launched medicines like Tecentriq, Alecensa, and Akribos, highlighting their approval and uptake in treating various cancers and multiple sclerosis. It addresses the challenge of biosimilar versions of Rituxan and emphasizes the company's focus on innovation and improving patient care. The status of the breast cancer drug Perjeta is also covered, noting its significant sales and potential as a growth driver following positive results from the affinity study.

What challenges are mentioned regarding the old best sellers like Rituxan?

What are the expected future contributions of Perjeta to the franchise?